Trial Profile
LONG TERM SAFETY FOLLOW UP OF PATIENTS ENROLLED IN THE PHASE I/II CLINICAL TRIAL OF HAEMATOPOIETIC STEM CELL GENE THERAPY FOR THE WISKOTT-ALDRICH SYNDROME(GTG 002-07 AND GTG 003-08)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs WASp gene therapy (Primary)
- Indications Wiskott-Aldrich syndrome
- Focus Adverse reactions; Pharmacodynamics
- Acronyms WAS FUP
- Sponsors Genethon
- 31 May 2021 Planned End Date changed from 1 Dec 2027 to 1 Oct 2032.
- 31 May 2021 Planned primary completion date changed from 1 Dec 2027 to 1 Oct 2032.
- 31 May 2021 Status changed from recruiting to active, no longer recruiting.